The most important change from the previous guideline is the recommendation that “curative” treatment with urate-lowering drugs should be offered to all patients with gout early in the course of their disease rather than waiting for them to develop troublesome, disabling symptoms.
This updated guideline is required because of
- the availability of new pharmaceutical treatment options
- recent increases in the incidence, prevalence and severity of gout
- continuing suboptimal management in both primary and secondary care
- better understanding of patient and provider barriers to effective care.
- Management of acute attacks
- Modification of lifestyle and risk factors
- Optimal use of urate-lowering therapies
Guideline Title: BSR Guideline for the Management of Gout
Corresponding Author: Edward Roddy, Research Institute for Primary Care and Health Sciences, Keele University, Keele, Staffordshire, UK.
Authors: Michelle Hui, Alison Carr, Stewart Cameron, Graham Davenport, Michael Doherty, Harry Forrester, Wendy Jenkins, Kelsey M Jordan, Christian D Mallen, Thomas M McDonald, George Nuki, Anthony Pywell, Weiya Zhang, Edward Roddy, for the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Audit and Guidelines Working Group